Related Experiment Video
Updated: May 28, 2026
04:41
Treatment with Locking Intramedullary Nailing for Intertrochanteric Fracture of the Femur Utilizing a New Awl with a Distal Positioner
Published on: June 6, 2025
Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?
R S Yoon1, J S Hwang, K S Beebe
1NYU Hospital for Joint Diseases, Department of Orthopaedic Surgery, 301 East 17th Street, New York, New York 10003, USA.
The Journal of Bone and Joint Surgery. British Volume
|October 5, 2011
Summary
Bisphosphonates effectively prevent fragility fractures in post-menopausal women. However, long-term use may be linked to rare atypical femoral fractures, prompting concern and research into this adverse effect.
Area of Science:
- Orthopedics
- Pharmacology
- Geriatrics
Background:
- Bisphosphonates are a primary treatment for preventing fragility fractures in millions of post-menopausal women.
- These drugs maintain bone density, reducing fracture incidence and associated healthcare costs.
- A rare complication, atypical subtrochanteric femoral fracture, has emerged as a concern with long-term bisphosphonate use.
Purpose of the Study:
- To review current information on atypical subtrochanteric femoral fractures.
- To explore the potential link between long-term bisphosphonate therapy and these fractures.
- To address the controversy and lack of management protocols for this adverse effect.
Main Methods:
- Literature review of studies on bisphosphonate therapy and atypical femoral fractures.
- Analysis of evidence regarding the association between drug duration and fracture occurrence.
- Examination of current clinical concerns and management strategies.
Main Results:
- Bisphosphonates have significantly reduced fragility fractures for over a decade.
- A controversial association exists between long-term bisphosphonate use and atypical subtrochanteric femoral fractures.
- Evidence supporting a definitive causal link remains debated, with no established management protocol.
Conclusions:
- While bisphosphonates are crucial for fracture prevention, the risk of atypical fractures requires careful consideration.
- Further research is needed to clarify the relationship and develop management guidelines.
- Balancing the benefits of bisphosphonates against potential rare adverse effects is essential for patient care.
